PressSeptember 1, 2022 Filament Health and ATMA Journey Centers Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial
PressAugust 31, 2022 Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
PressAugust 31, 2022 PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022
PressAugust 31, 2022 Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
PressAugust 30, 2022 Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
PressAugust 30, 2022 Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results
PressAugust 30, 2022 Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
PressAugust 29, 2022 Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo Branded Ingredient from FDA
PressAugust 26, 2022 B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial
PressAugust 26, 2022 PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
PressAugust 26, 2022 Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
PressAugust 26, 2022 SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
PressAugust 26, 2022 PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th
